Case report flags rebound neurologic signs after canine dialysis
Bottom line
A new case report in the Journal of Veterinary Emergency and Critical Care describes what the authors say is the first documented instance of recurrent neurologic signs caused by drug redistribution after extracorporeal toxin removal in a dog treated for combined phenobarbital and zonisamide intoxication. The report, by Mario A. Barenas and Jonathan D. Foster, adds a cautionary note to a modality that has otherwise been reported as effective and safe for severe phenobarbital intoxication in dogs. Prior published canine reports described rapid neurologic recovery during hemodialysis without adverse effects, making this rebound phenomenon a notable development for emergency and nephrology teams. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the case highlights that clinical improvement during dialysis may not be the end of the story when highly relevant anticonvulsants are involved. Phenobarbital is a recognized dialyzable toxin in veterinary extracorporeal therapy, and zonisamide is widely used in dogs, with known pharmacokinetic interaction when given with phenobarbital. That means clinicians managing overdose cases may need to anticipate delayed rebound signs, extend post-dialysis monitoring, and be cautious about declaring treatment success based only on intradialytic neurologic improvement. (vin.com)
What to watch: Whether this case prompts more formal guidance on post-hemodialysis monitoring, repeat drug-level checks, or consideration of rebound risk in veterinary toxicology protocols. (vin.com)
Key facts
- Article type
- Canine case report
- Journal
- Journal of Veterinary Emergency and Critical Care
- Authors
- Mario A. Barenas and Jonathan D. Foster
- Case
- Recurrent neurologic signs after hemodialysis
- Toxins involved
- Phenobarbital and zonisamide intoxication
- Key finding
- First documented veterinary report of drug redistribution complicating extracorporeal toxin removal in this setting
- Clinical implication
- Neurologic signs recurred after apparent improvement during hemodialysis
- Context
- Prior canine reports described rapid neurologic recovery during hemodialysis without adverse effects
A new canine case report is putting a finer point on a familiar rescue therapy. In the Journal of Veterinary Emergency and Critical Care, Mario A. Barenas and Jonathan D. Foster describe recurrent neurologic signs after hemodialysis for phenobarbital and zonisamide intoxication in a dog, which the abstract identifies as the first documented veterinary report of a drug redistribution phenomenon complicating extracorporeal toxin removal in this setting. That matters because hemodialysis has been increasingly recognized as a high-value option for severe intoxications involving dialyzable drugs, including phenobarbital. (vin.com)
Until now, the published veterinary literature around phenobarbital intoxication and hemodialysis had been relatively reassuring. A 2020 report in the same journal described two dogs with severe phenobarbital intoxication that underwent 3-hour hemodialysis sessions, returned to normal mentation by the end of treatment, and experienced no negative side effects. More broadly, veterinary extracorporeal therapy references have long listed phenobarbital among toxins for which hemodialysis can be considered when conventional therapy is inadequate or when rapid toxin removal is needed. (pubmed.ncbi.nlm.nih.gov)
What appears to distinguish this new case is the post-dialysis rebound. While the full article details were not fully accessible in the search results, the abstract states that neurologic signs recurred after hemodialysis and frames the event as evidence of drug redistribution. In practical terms, that suggests toxin movement from peripheral compartments back into the vascular space after extracorporeal removal, a phenomenon recognized in toxicology literature and dialysis medicine, but not previously documented in a veterinary extracorporeal intoxication case like this one. (dickyricky.com)
The drug combination is also clinically relevant. Zonisamide is now commonly used in canine seizure management, and phenobarbital remains a mainstay first-line antiseizure medication. Prior pharmacokinetic work shows phenobarbital increases zonisamide clearance and shortens its elimination half-life in dogs, and consensus guidance has recommended serum monitoring when the two drugs are used together, especially if seizure control changes. That interaction does not directly explain a dialysis rebound event, but it does underscore how complicated interpretation can become when two antiseizure drugs with different distribution and elimination characteristics are involved in an overdose case. (pubmed.ncbi.nlm.nih.gov)
I did not find a separate press release or public expert commentary specifically reacting to this case report. But the surrounding literature provides useful context: zonisamide has been associated with a range of adverse effects in dogs, from behavioral abnormalities to renal tubular acidosis and rare hepatopathy, while phenobarbital intoxication and chronic toxicity remain familiar concerns in practice. That broader experience may make clinicians more receptive to the report’s central message, which is less about questioning dialysis itself and more about recognizing that successful extracorporeal clearance can be followed by clinically important rebound signs. (pmc.ncbi.nlm.nih.gov)
Why it matters: For emergency, critical care, nephrology, and neurology teams, this case is a reminder to pair toxin removal with a monitoring plan. If rebound neurologic signs can occur after apparent improvement, then post-dialysis observation, repeat neurologic assessment, and follow-up drug concentration testing may deserve more emphasis in overdose protocols, especially at referral centers offering extracorporeal therapies. It also reinforces the need to counsel pet parents that hemodialysis can be highly effective, but recovery may not always be linear in the first hours after treatment. That’s an inference from the available literature and abstract, not a formal guideline change. (vin.com)
What to watch: The next step will be whether additional case reports surface, whether the authors publish more detailed pharmacokinetic interpretation, and whether specialty groups begin incorporating rebound-risk language into clinical teaching or extracorporeal treatment protocols for veterinary toxicology. (vin.com)